DeCODE Genetics initiated patient enrollment in the pivotal Phase III trial for DG031, the company’s lead developmental compound for the prevention of heart attack. The multicenter Phase III trial will be randomized, double-blind, placebo- controlled, and will enroll 3,400 patients with a history of recent heart attack. The trial, the Leukotrienes in Coronary Artery Disease, or LTCAD study, will focus on the group at highest identifiable risk of heart attack through the pathway targete...